Business Description
Oramed Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US68403P2039
Total Employee Number:
13Description
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 86.52 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-EBITDA | 0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12 | |||||
3-Year EPS without NRI Growth Rate | 34.8 | |||||
3-Year FCF Growth Rate | 29 | |||||
3-Year Book Growth Rate | 9.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.48 | |||||
9-Day RSI | 61.12 | |||||
14-Day RSI | 60.39 | |||||
3-1 Month Momentum % | 5.26 | |||||
6-1 Month Momentum % | 23.71 | |||||
12-1 Month Momentum % | 66.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.45 | |||||
Quick Ratio | 6.45 | |||||
Cash Ratio | 6.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.43 | |||||
Dividend Payout Ratio | 0.14 | |||||
Forward Dividend Yield % | 5.43 | |||||
5-Year Yield-on-Cost % | 5.43 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 5.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -523.8 | |||||
OCF Margin % | -427.05 | |||||
ROE % | 58.72 | |||||
ROA % | 53.43 | |||||
ROIC % | -12.71 | |||||
3-Year ROIIC % | 29.83 | |||||
ROC (Joel Greenblatt) % | 4047.87 | |||||
ROCE % | 39.98 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1.78 | |||||
Forward PE Ratio | 1.99 | |||||
PE Ratio without NRI | 2.62 | |||||
Price-to-Owner-Earnings | 1.65 | |||||
PS Ratio | 97.87 | |||||
PB Ratio | 0.79 | |||||
Price-to-Tangible-Book | 0.79 | |||||
EV-to-EBIT | 1.56 | |||||
EV-to-EBITDA | 1.56 | |||||
EV-to-Revenue | 61.59 | |||||
EV-to-Forward-Revenue | 0.44 | |||||
EV-to-FCF | -11.76 | |||||
Price-to-Projected-FCF | 4.89 | |||||
Price-to-Graham-Number | 0.3 | |||||
| Price-to-Net-Current-Asset-Value | 5 | |||||
| Price-to-Net-Cash | 5.35 | |||||
Earnings Yield (Greenblatt) % | 64.1 | |||||
FCF Yield % | -5.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ORMP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oramed Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2 | ||
| EPS (TTM) ($) | 2.58 | ||
| Beta | 1.1466 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.16 | ||
| Volatility % | 40.79 | ||
| 14-Day RSI | 60.39 | ||
| 14-Day ATR ($) | 0.307788 | ||
| 20-Day SMA ($) | 4.1135 | ||
| 12-1 Month Momentum % | 66.67 | ||
| 52-Week Range ($) | 1.975 - 5.19 | ||
| Shares Outstanding (Mil) | 40.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oramed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oramed Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 131 days | ||
| General meeting for 2025 | 2026-08-19 10:00 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 40 days | ||
| First quarter earnings results for 2026 | 2026-05-19 | 4.29 (-7.34%) | ||
| Annual report for 2025 | 2026-03-26 | 3.50 (+1.45%) | ||
| USD 0.250000 Cash Dividend | 2026-01-16 | 3.69 (-0.54%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 2.47 (+4.22%) | ||
| General meeting for 2024 | 2025-08-19 10:00 | 2.08 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.12 (+0.95%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 2.21 (-2.21%) |
Show
Entries
Oramed Pharmaceuticals Inc Frequently Asked Questions
What is Oramed Pharmaceuticals Inc(ORMP)'s stock price today?
The current price of ORMP is $4.60. The 52 week high of ORMP is $5.19 and 52 week low is $1.98.
When is next earnings date of Oramed Pharmaceuticals Inc(ORMP)?
The next earnings date of Oramed Pharmaceuticals Inc(ORMP) is 2026-08-14 Est..
Does Oramed Pharmaceuticals Inc(ORMP) pay dividends? If so, how much?
The Dividend Yield %  of Oramed Pharmaceuticals Inc(ORMP) is 5.43% (As of Today), Highest Dividend Payout Ratio of Oramed Pharmaceuticals Inc(ORMP) was 0.14. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Oramed Pharmaceuticals Inc(ORMP) is 5.43%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:ORMP
No articles.
Press Release
Articles on Oramed Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers